Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT – Get Rating) has been given an average recommendation of “Hold” by the eleven analysts that are currently covering the firm, Marketbeat.com reports. Seven research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $22.10.
A number of research firms have recently weighed in on ICPT. StockNews.com lowered Intercept Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, August 4th. SVB Leerink decreased their price target on Intercept Pharmaceuticals from $27.00 to $21.00 and set a “market perform” rating for the company in a research report on Friday, July 8th. Raymond James increased their price target on Intercept Pharmaceuticals from $23.00 to $26.00 and gave the company an “outperform” rating in a research report on Thursday, August 4th. B. Riley decreased their price target on Intercept Pharmaceuticals from $30.00 to $28.00 and set a “buy” rating for the company in a research report on Monday, August 22nd. Finally, Needham & Company LLC decreased their price target on Intercept Pharmaceuticals from $25.00 to $22.00 and set a “buy” rating for the company in a research report on Friday, July 8th.
Intercept Pharmaceuticals Stock Down 0.8 %
ICPT stock opened at $17.00 on Friday. Intercept Pharmaceuticals has a twelve month low of $10.81 and a twelve month high of $21.25. The stock’s 50 day moving average is $16.03 and its 200-day moving average is $15.89. The firm has a market capitalization of $506.60 million, a PE ratio of -7.83 and a beta of 1.09.
Institutional Trading of Intercept Pharmaceuticals
A number of large investors have recently bought and sold shares of ICPT. Adage Capital Partners GP L.L.C. purchased a new stake in Intercept Pharmaceuticals in the fourth quarter worth $20,086,000. Eventide Asset Management LLC grew its position in shares of Intercept Pharmaceuticals by 144.3% in the first quarter. Eventide Asset Management LLC now owns 800,000 shares of the biopharmaceutical company’s stock valued at $13,016,000 after purchasing an additional 472,556 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Intercept Pharmaceuticals by 21.2% in the first quarter. Vanguard Group Inc. now owns 2,389,249 shares of the biopharmaceutical company’s stock valued at $38,873,000 after purchasing an additional 417,490 shares in the last quarter. Jupiter Asset Management Ltd. purchased a new position in shares of Intercept Pharmaceuticals in the first quarter valued at $5,152,000. Finally, Renaissance Technologies LLC grew its position in shares of Intercept Pharmaceuticals by 82.8% in the second quarter. Renaissance Technologies LLC now owns 393,400 shares of the biopharmaceutical company’s stock valued at $5,433,000 after purchasing an additional 178,200 shares in the last quarter. 86.00% of the stock is owned by hedge funds and other institutional investors.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults.
- Get a free copy of the StockNews.com research report on Intercept Pharmaceuticals (ICPT)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.